⚕️ Medical Disclaimer
⚕️ Medical Disclaimer: Educational identity article for bromantane (Ladasten). Not FDA-approved for cognition or fatigue in the United States. Not a dosing protocol.
What Bromantane Is
Bromantane (brand Ladasten in Russia; chemical name N-(2-adamantyl)-N-(para-bromophenyl)amine) is an adamantane-derived actoprotector — a synthetic adaptogen class studied for physical and mental performance under stress, distinct from classical amphetamine-like stimulants. It is a small molecule, not a peptide, and not Noopept, Semax, or Selank.
Identity leaf: /peptides/bromantane. This essay expands mechanism literacy, opened Russian-line clinical abstracts, and the Noopept co-use folklore problem.
Mechanism Notes From Opened Literature
Oliynyk and Oh (PMC3762282, “The Pharmacology of Actoprotectors”) summarizes bromantane as an adamantane actoprotector permitted for medical use in Russia (Ladasten), with oral bioavailability about 42%, high lipophilicity, and deposition in adipose tissue. The review describes dopaminergic activation without classical stimulant hyperstimulation, GABA-ergic modulation, and immunomodulatory claims drawn from the Russian pharmacology tradition (Morozov / Seredenin lineage).
English secondary sources and Russian-line papers commonly frame bromantane as enhancing dopamine synthesis via upregulation of tyrosine hydroxylase rather than as a simple reuptake-blocker stimulant. Exact molecular “first receptor” claims remain incompletely settled in the opened reviews — treat mechanism as dopaminergic / actoprotector-class, not as amphetamine equivalence.
Russian Clinical Files We Can Point To
Neznamov et al. (PubMed PMID 19491814): randomized blind comparative study of ladasten versus placebo in neurasthenia over a 28-day monotherapy window (plus washout / final placebo week in the design). The abstract reports faster and greater reduction of asthenic syndrome symptoms versus placebo and no withdrawal syndrome after stopping — framed as low addictive potential in that analysis.
Syunyakov / Neznamov / Seredenin pilot work (PubMed PMID 16995430): clinical pilot in psychogenic asthenic disorder describing combined stimulant and anxiolytic-like effects unusual for classical psychostimulants.
Those are Russian-tradition clinical files accessible via PubMed abstracts we opened. They are not a US NDA for ADHD, depression, or “study drugs.” Milligram schedules belong to Russian labeling and full papers — this essay will not invent a DIY titration chart from forum lore.
Bromantane and Noopept — Anecdote Unless You Opened a Combo Trial
Forum stacks often pair bromantane with Noopept for study or physical work. We opened no published co-administration RCT of that pair. Treat the stack as community anecdote, not synergy pharmacology. See the Noopept leaf’s evidenceLimits language — same rule, now with a live bromantane leaf instead of a dead link.
Semax and Selank are different Russian-line peptides with their own leaves. Shared “nootropic aisle” marketing is not shared identity.
Evidence Limits
Not an FDA-approved cognition or fatigue drug in the United States. Not a peptide. Not interchangeable with modafinil, amphetamines, or racetams. Gray-market powders have unknown purity. WADA and sport rules may restrict related stimulants/actoprotectors — check the current prohibited list if you compete.
This site will not treat ADHD, anxiety disorders, or depression from a bromantane page.